A total of 140 patients with HBeAg-positive CHB were randomly divided into treatment groups for LDT monotherapy ( n = 75 ; 600 mg orally , once daily ) and LDT+ADV combination therapy ( n = 65 ; LDT 600 mg plus ADV 10 mg orally , once daily ) .